XML 19 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 29, 2019
Dec. 28, 2018
 [1]
Current assets:    
Cash and cash equivalents $ 373,937 $ 314,775
Short-term investments 425,713 378,559
Trade and other receivables 107,670 162,771
Other receivables 7,445 16,056
Inventory, net 10,143 9,838
Unbilled collaboration revenue 7,244 0
Prepaid expenses and other current assets 14,146 15,017
Total current assets 946,298 897,016
Long-term investments 218,619 157,187
Long-term restricted cash and investments 1,100 1,100
Property and equipment, net 50,553 50,897
Operating lease right-of-use assets 13,921 5,867
Deferred tax assets, net 243,717 244,111
Goodwill 63,684 63,684
Other long-term assets 3,902 2,424
Total assets 1,541,794 1,422,286
Current liabilities:    
Accounts payable 9,748 10,901
Accrued clinical trial liabilities 23,055 18,231
Accrued compensation and benefits 22,550 32,142
Rebates and fees due to customers 19,708 14,954
Accrued collaboration liabilities 7,556 7,419
Current portion of deferred revenue 2,376 0
Other current liabilities 40,139 21,825
Total current liabilities 125,132 105,472
Long-term portion of lease liabilities 19,958 12,178
Long-term portion of deferred revenue 8,323 15,897
Other long-term liabilities 3,361 1,286
Total liabilities 156,774 134,833
Commitments
Stockholders’ equity    
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 301,519,885 and 299,876,080 at March 31, 2019 and December 31, 2018, respectively 302 300
Additional paid-in capital 2,188,578 2,168,217
Accumulated other comprehensive income (loss) 728 (701)
Accumulated deficit (804,588) (880,363)
Total stockholders’ equity 1,385,020 1,287,453
Total liabilities and stockholders’ equity $ 1,541,794 $ 1,422,286
[1] The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.